CAR-T Cell Therapy Market Worth $20,566.5 Million By 2029 | CAGR: 31.6 %

The global CAR-T cell therapy market size is expected to reach USD 20,566.5 million by 2029 according to a new study published by Polaris Market Research. The report “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2022 – 2029” provides deep dive insights on the current market dynamics and gives a detailed analysis on future growth trends of this market.

Chimeric antigen receptor CAR T therapy is a type of immunotherapy that modifies the immune system of a cancer patient to make it more effective at detecting and killing cancer cells. A protein is added to the surface of CAR T cells during the manufacturing process to assist them in acquiring this focus. This protein is called a chimeric antigen receptor, or CAR.

Diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, follicular lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukaemia (ALL) in pediatric and young adult patients up to the age of 25 are now treated using CAR T treatment. The US Food and Drug Administration has approved five CAR T medicines as of March 2021. (FDA).

CAR-T treatment is growing rapidly due to rising cancer cases. Additionally, technical advancements of diagnostic techniques in this industry, growing awareness among the people, and the increase in the geriatric population are contributing to and providing significant potential for industry growth.

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/car-t-cell-therapy-market/request-for-sample

North America is dominating the CAR-T market due to the number of life sciences companies focusing on the development and commercial manufacturing of CAR T-cells, as well as improvements in quality control systems in North America.

Some key players in the global industry include Amgen Inc. (US), Bellicum Pharmaceuticals, Inc. (US), Caribou Biosciences, Inc. (US), Celgene Corporation, Bluebird Bio (US), Intellia Therapeutics, Johnson & Johnson, Cellectis, Celyad, Gilead Sciences, Inc., Merck KGaA, Nanjing Legend Biotechnology Co., Ltd., Noile-Immune Biotech, Novartis International AG, Pfizer Inc., Sangamo Therapeutics, Inc., Servier Laboratories.

Polaris Market Research has segmented the CAR-T cell therapy market report on the basis of target antigens, indications, and region:

CAR-T Cell Therapy, Target Antigens Outlook (Revenue, USD Million, 2017 – 2029)

• CD19/CD22
• BCMA (B-Cell Maturation Antigen)
• Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13R?2, LewisY)

CAR-T Cell Therapy, Indication Outlook (Revenue, USD Million, 2017 – 2029)

• Diffuse Large B-Cell Lymphoma (DLBCL)
• Acute Lymphoblastic Leukemia (ALL)
• Chronic Lymphocytic Leukemia (CLL)
• Multiple Myeloma (MM)
• Follicular Lymphoma (FL)
• Others

CAR-T Cell Therapy Regional Outlook (Revenue, USD Million, 2017 – 2029)

• North America
  • U.S
  • Canada
• Europe
  • France
  • Germany
  • Switzerland
• Asia Pacific
  • China
  • Japan
• Rest of World